AngioDynamics, Inc. (ANGO) Price Prediction 2026–2050

AngioDynamics, Inc. is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium.

The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators.

AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics, Inc. (ANGO) is the company behind a portfolio of medical devices aimed at vascular, oncologic, and surgical applications. Current price is $11.92 per share, with a market capitalization of $492.52M and a market-rank of 3049.

The stock sits within a 30-day technical context marked by a bullish tilt in sentiment, with a RSI14 at 60 and moving averages showing price interaction near key levels. The 50-day simple moving average is $10.85 and the 200-day simple moving average is $11.18, with a defined support at $10.24 and resistance at $11.96. Over the next 30 days, the stock has traded within a range of $10.47 to $13.57, and the stock’s annualized volatility stands around 40%.

The forecast shows a neutral view for 2026 with an average price of $11.92, followed by a bullish trajectory through 2050, underscoring potential upside in the longer term.

The multi-year forecast shows a bullish trajectory after 2026, with annual averages rising from $11.92 in 2026 to higher levels in subsequent years. In 2030, the average forecast is $26.73 with an ROI of 124.3% and a bullish sentiment. By 2040, the average is $82.84 with an ROI of 595% and continued bullish sentiment, and by 2050 the average is $182.53 with an ROI of 1431.3% and bullish sentiment.

These figures illustrate meaningful upside potential over the longer horizon, though they are estimates and not guarantees. Investors should consider that outcomes can differ from projections and that market conditions can change.